StockwhizBeta
← Startup News
Funding round
Healthcare

Seawolf Therapeutics Raises $100 Million to Advance DNA-Based Therapeutics

Stockwhiz
0 views
Seawolf Therapeutics

Seawolf Therapeutics emerged from stealth with $100 million raised through seed and Series A financing involving Versant Ventures, MPM BioImpact, Novartis Venture Fund and other investors. The company also announced a Sanofi collaboration with up to $1.2 billion in potential milestones, plus royalties.

At a Glance

Seawolf Therapeutics

USAHealthcare
Raised
$100 million
Round
Seed and Series A
Investors
8
Investors
Versant VenturesMPM BioImpactNovartis Venture FundEli Lilly and CompanyCRISPR Therapeutics AGSixty Degree CapitalAlexandria Venture InvestmentsPathway to Cures
Target market
Metabolic and rare diseases
Use of funds
Advance the portfolio of therapeutics leveraging the TRIDENT redosable lipid nanoparticle-based DNA delivery system

Key people

  • Elizabeth Alcamo, PhD

    President & CEO

  • Tom Woiwode, PhD

    Managing Director

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in

Quick Answers

What is the latest news about Seawolf Therapeutics?

Seawolf Therapeutics emerged from stealth with $100 million raised through seed and Series A financing involving Versant Ventures, MPM BioImpact, Novartis Venture Fund and other investors. The company also announced a Sanofi collaboration with up to $1.2 billion in potential milestones, plus royalties.

What does Seawolf Therapeutics do?

Seawolf Therapeutics is a privately held biotechnology company headquartered in San Diego, CA. It develops therapeutics using a proprietary lipid nanoparticle-based DNA delivery platform designed to enable long-term, stable expression of therapeutic proteins.

How much did Seawolf Therapeutics raise?

Seawolf Therapeutics raised $100 million in its Seed and Series A.

Who invested in Seawolf Therapeutics?

Investors named in this Seed and Series A include Versant Ventures, MPM BioImpact, Novartis Venture Fund, Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments and Pathway to Cures.

How will Seawolf Therapeutics use the funding?

Seawolf Therapeutics plans to use the money for advance the portfolio of therapeutics leveraging the TRIDENT redosable lipid nanoparticle-based DNA delivery system.

Where is Seawolf Therapeutics based?

Seawolf Therapeutics is based in USA.

Who are the key people at Seawolf Therapeutics?

Key people named in this report: Elizabeth Alcamo, PhD (President & CEO) and Tom Woiwode, PhD (Managing Director).